IBA secures contract worth 80 million euros in China


IBA (Ion Beam Applications S.A.) has signed a contract with a Chinese company to install a proton therapy centre in the city of Qingdao, in China. This contract is believed to be worth over 80 million euros for IBA and includes a long-term service agreement.

IBA will equip the new centre with 5 cancer treatment rooms, 4 fitted with a rotating gantry and 1 room with a fixed beam, all with the latest generation of technologies for intensity modulated proton therapy (IMPT). The contract also includes an operations and maintenance agreement. The objective is to treat the first patient at the centre by late 2018.

Olivier Legrain, CEO of IBA, commented: “This new collaboration further strengthens IBA’s world leading position in proton therapy. This centre will be one of the largest in the world and equipped with the most technically advanced therapeutic and imaging solutions. IBA is pleased to be bringing its innovative cancer treatment methods to patients in China.”

The Chinese partner added: "We want the most innovative treatments for our cancer patients in order to fight this serious disease effectively; proton therapy will help give our team of oncologists the critical tools to fight cancer. Our new multi-room solution, including Pencil Beam Scanning technology, will be installed by IBA and will allow us to ‘paint’ tumours with a super-fine beam of protons, destroying cancer cells whilst leaving surrounding healthy tissue untouched.”

IBA is a Belgian company, based in Louvain-la-Neuve and employing 1,300 people in Belgium and worldwide. It develops innovative, integrated systems for the diagnosis and treatment of cancer. The company is the world leader in proton therapy, the most advanced form of radiotherapy to date. IBA also develops dosimetry solutions for radiotherapy and radiology, as well as particle accelerators for medical and industrial applications. IBA shares are listed on Euronext.